The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome

RegulatoryapprovedasedebartPositive

AI Analysis

Summary

Lundbeck's investigational anti-ACTH monoclonal antibody asedebart has received Orphan Drug Designation from the FDA for treating endogenous Cushing's syndrome, a rare endocrine disorder. The designation supports development of this novel therapeutic approach.

Outcome Details

Orphan Drug Designation granted by U.S. FDA

Importance:6/10

Sentiment:

0.70

orphan drug designationmonoclonal antibodyendocrine disorderrare diseaseFDA regulatory

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Pharma on September 11, 2026 8:21 AM

Read Original